Propanc Biopharma reports preclinical data showing 90% tumor inhibition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. PNFP
10. NDAQ

Go back to Propanc Biopharma reports preclinical data showing 90% tumor inhibition

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

August 6, 2026 8:30 AM EDT

Accelerates Phase 1b First-in-Human Trial Timeline

MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (Propanc or the Company), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and treatment-resistant solid tumors.

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, 3 times weekly intravenous PRP achieved:

Greater than 90% mean tumor growth inhibition... More